Can-Fite BioPharma Ltd. CANF.TA Stock
Can-Fite BioPharma Ltd. Price Chart
Can-Fite BioPharma Ltd. CANF.TA Financial and Trading Overview
| Can-Fite BioPharma Ltd. stock price | 2.8 ILA |
| Previous Close | 2.7 ILA |
| Open | 2.6 ILA |
| Bid | 2.6 ILA x N/A |
| Ask | 2.7 ILA x N/A |
| Day's Range | 2.6 - 2.7 ILA |
| 52 Week Range | 2.1 - 9.3 ILA |
| Volume | 2.68M ILA |
| Avg. Volume | 4.87M ILA |
| Market Cap | 3.31B ILA |
| Beta (5Y Monthly) | 0.866 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 ILA |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CANF.TA Valuation Measures
| Enterprise Value | 25.18M ILA |
| Trailing P/E | N/A |
| Forward P/E | -1.4361702 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4212.825 |
| Price/Book (mrq) | 675 |
| Enterprise Value/Revenue | 32.076 |
| Enterprise Value/EBITDA | -2.67 |
Trading Information
Can-Fite BioPharma Ltd. Stock Price History
| Beta (5Y Monthly) | 0.866 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 9.3 ILA |
| 52 Week Low | 2.1 ILA |
| 50-Day Moving Average | 2.79 ILA |
| 200-Day Moving Average | 3.12 ILA |
CANF.TA Share Statistics
| Avg. Volume (3 month) | 4.87M ILA |
| Avg. Daily Volume (10-Days) | 3.72M ILA |
| Shares Outstanding | 1.22B |
| Float | 1.22B |
| Short Ratio | N/A |
| % Held by Insiders | 0.030% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -951.53% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -53.96% |
| Return on Equity (ttm) | -142.16% |
Income Statement
| Revenue (ttm) | 785K ILA |
| Revenue Per Share (ttm) | 0.001 ILA |
| Quarterly Revenue Growth (yoy) | -3.89% |
| Gross Profit (ttm) | 810K ILA |
| EBITDA | -9430000 ILA |
| Net Income Avi to Common (ttm) | -9001000 ILA |
| Diluted EPS (ttm) | -0.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 7.94M ILA |
| Total Cash Per Share (mrq) | 0.006 ILA |
| Total Debt (mrq) | 51K ILA |
| Total Debt/Equity (mrq) | 0.97 ILA |
| Current Ratio (mrq) | 4.101 |
| Book Value Per Share (mrq) | 0.004 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Can-Fite BioPharma Ltd.
| Country | Israel |
| State | N/A |
| City | Petah Tikva |
| Address | 10 Bareket Street |
| ZIP | 4951778 |
| Phone | 972 3 924 1114 |
| Website | https://www.canfite.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Q&A For Can-Fite BioPharma Ltd. Stock
What is a current CANF.TA stock price?
Can-Fite BioPharma Ltd. CANF.TA stock price today per share is 2.8 ILA.
How to purchase Can-Fite BioPharma Ltd. stock?
You can buy CANF.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Can-Fite BioPharma Ltd.?
The stock symbol or ticker of Can-Fite BioPharma Ltd. is CANF.TA.
Which industry does the Can-Fite BioPharma Ltd. company belong to?
The Can-Fite BioPharma Ltd. industry is Biotechnology.
How many shares does Can-Fite BioPharma Ltd. have in circulation?
The max supply of Can-Fite BioPharma Ltd. shares is 14.97M.
What is Can-Fite BioPharma Ltd. Price to Earnings Ratio (PE Ratio)?
Can-Fite BioPharma Ltd. PE Ratio is now.
What was Can-Fite BioPharma Ltd. earnings per share over the trailing 12 months (TTM)?
Can-Fite BioPharma Ltd. EPS is -0.04 ILA over the trailing 12 months.
Which sector does the Can-Fite BioPharma Ltd. company belong to?
The Can-Fite BioPharma Ltd. sector is Healthcare.